Johns Hopkins Arthritis Center

Home / Arthritis News / Infliximab (Remicade) in combination with methotrexate, is now indicated for reducing signs and symptoms and inhibiting the progression of structural damage in rheumatoid arthritis patients

Infliximab (Remicade) in combination with methotrexate, is now indicated for reducing signs and symptoms and inhibiting the progression of structural damage in rheumatoid arthritis patients

By


Inflimab, In Combination with Methotrexate, is Indicated for Inhibition of Progression of Structural Damage in RA Patients

Infliximab (Remicade®), in combination with methotrexate, is now indicated for reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate. Approval from the Food and Drug Administration (FDA) for the expanded indication came as a result of radiographic and clinical results from a phase III randomized, double-blind, multi-center trial of 420 adults. (more details on study)

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.